<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">PPT1 Promotes Growth and Inhibits Ferroptosis of Oral Squamous Cell Carcinoma Cells</title>
				<funder ref="#_YW3DcDV">
					<orgName type="full">Shanghai Municipal Natural Science Foundation</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Qingqiong</forename><surname>Luo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Clinical Immunology</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Shanghai Ninth People&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">Shanghai Jiao Tong University</orgName>
								<address>
									<postCode>200011</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Shanghai Skin Disease Hospital</orgName>
								<orgName type="institution" key="instit2">Tongji University</orgName>
								<address>
									<postCode>200443</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sheng</forename><surname>Hu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="laboratory">Central Laboratory</orgName>
								<orgName type="institution" key="instit1">Shanghai Skin Disease Hospital</orgName>
								<orgName type="institution" key="instit2">Tongji University</orgName>
								<address>
									<postCode>200443</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yijie</forename><surname>Tang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Shanghai Skin Disease Hospital</orgName>
								<orgName type="institution" key="instit2">Tongji University</orgName>
								<address>
									<postCode>200443</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dandan</forename><surname>Yang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Shanghai Skin Disease Hospital</orgName>
								<orgName type="institution" key="instit2">Tongji University</orgName>
								<address>
									<postCode>200443</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Qilong</forename><surname>Chen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Clinical Immunology</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Shanghai Ninth People&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">Shanghai Jiao Tong University</orgName>
								<address>
									<postCode>200011</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="laboratory">Central Laboratory</orgName>
								<orgName type="institution" key="instit1">Shanghai Skin Disease Hospital</orgName>
								<orgName type="institution" key="instit2">Tongji University</orgName>
								<address>
									<postCode>200443</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<address>
									<postCode>2174/0115680096294098240123104657</postCode>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">PPT1 Promotes Growth and Inhibits Ferroptosis of Oral Squamous Cell Carcinoma Cells</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">84AA762A784C29E8FB145D964BDE6926</idno>
					<idno type="DOI">10.2174/0115680096294098240123104657</idno>
					<note type="submission">Received: November 21, 2023 Revised: December 12, 2023 Accepted: January 17, 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-06-12T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Oral squamous cell carcinoma</term>
					<term>differentially expressed genes</term>
					<term>palmitoyl protein thioesterase 1</term>
					<term>proliferation</term>
					<term>glutathione peroxidase 4</term>
					<term>ferroptosis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Background: Oral Squamous Cell Carcinoma (OSCC) is one of the most prevalent cancers with poor prognosis in the head and neck. Elucidating molecular mechanisms underlying OSCC occurrence and development is important for the therapy. Dysregulated palmitoylation-related enzymes have been reported in several cancers but OSCC.</p><p>Objective: To explore the role of palmitoyl protein thioesterase 1 (PPT1) in OSCC.</p><p>Methods: Differentially Expressed Genes (DEGs) and related protein-protein interaction networks between normal oral epithelial and OSCC tissues were screened and constructed via different online databases. Tumor samples from 70 OSCC patients were evaluated for the relationship between PPT1 expression level and patients'clinic characteristics. The role of PPT1 in OSCC proliferation and metastasis was studied by functional experiments, including MTT, colony formation, EdU incorporation and transwell assays. Lentivirus-based constructs were used to manipulate the gene expression. FerroOrange probe and malondialdehyde assay were used to determine ferroptosis. Growth of OSCC cells in vivo was investigated by a xenograft mouse model.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p>A total of 555 DEGs were obtained, and topological analysis revealed that the PPT1 and GPX4 might play critical roles in OSCC. Increased PPT1 expression was found to be correlated with poor prognosis of OSCC patients. PPT1 effectively promoted the proliferation, migration and invasion while inhibiting the ferroptosis of OSCC cells. PPT1 affected the expression of glutathione peroxidase 4 (GPX4).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p>PPT1 promoted growth and inhibited ferroptosis of OSCC cells. PPT1 might be a potential target for OSCC therapy.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">INTRODUCTION</head><p>Oral Squamous Cell Carcinoma (OSCC) is the most common cancer of the oral cavity and lips. In 2020, about 377,713 new cases and 177,757 deaths were reported worldwide <ref type="bibr">[1]</ref><ref type="bibr" target="#b2">[2]</ref><ref type="bibr" target="#b4">[3]</ref>. Due to chronic alcohol consumption, smoking and betel nut chewing, the prevalence of OSCC in South Central Asia was relatively much higher <ref type="bibr" target="#b2">[2,</ref><ref type="bibr" target="#b6">4,</ref><ref type="bibr" target="#b8">5]</ref>. Although new therapies are continuously introduced in cancer treatment, the overall survival rate of OSCC has no significant improvement, and advanced OSCC has an even lower 5year survival rate of approximately 20% <ref type="bibr" target="#b10">[6]</ref><ref type="bibr" target="#b12">[7]</ref><ref type="bibr" target="#b14">[8]</ref>. To a certain extent, inherent or acquired resistance to therapeutic agents * Address correspondence to this author at the Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, <ref type="bibr">Shanghai, 200443, China;</ref><ref type="bibr">E-mail: cqlw1975@126.com</ref> in patients with OSCC may contribute to treatment failure <ref type="bibr" target="#b16">[9]</ref><ref type="bibr">[10]</ref><ref type="bibr" target="#b19">[11]</ref>. Therefore, further delineation of the molecular mechanisms underlying OSCC occurrence and development is important for the establishment of effective therapeutic strategies.</p><p>Tumors are distinguished by continuous cell proliferation, cell death resistance, increased cell invasion and metastasis etc. A variety of oncogenes and tumor suppressors regulates these processes. Posttranslational Modifications (PTMs) such as SUMOylation, acetylation, phosphorylation, lipidation, glycosylation etc., are involved in the modification of related oncogenes and tumor suppressors <ref type="bibr">[12]</ref><ref type="bibr">[13]</ref><ref type="bibr">[14]</ref><ref type="bibr" target="#b24">[15]</ref><ref type="bibr" target="#b26">[16]</ref>. Recently, protein palmitoylation has attracted the interest of several researchers. As a reversible lipid modification, palmitoylation is characterized by the addition of 16-carbon palmitate to cysteine residues via the thioester bond <ref type="bibr">[17]</ref>. In this way, the modified protein changes its hydrophobicity, localization, stability and interactions with other proteins, which leads to the activation or inhibition of related signaling pathways <ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr" target="#b30">[19]</ref>. The zinc finger DHHC-type containing (ZDH-HC) protein family catalyze protein palmitoylation, while palmitoyl protein thioesterase 1/2 (PPT1/2), acyl-protein thioesterase 1/2 (APT1/2) and alpha/beta hydrolase-containing protein 17A/B/C (ABHD17A/B/C) mediate protein depalmitoylation <ref type="bibr" target="#b30">[19,</ref><ref type="bibr" target="#b32">20]</ref>. There are various reports on the dysregulation of palmitoylation-related enzymes in cancers like breast cancer, hepatocellular carcinoma (HCC), melanoma, prostate cancer, hematopoietic malignancies etc., which affect tumor cell growth or immune regulation <ref type="bibr">[21]</ref><ref type="bibr">[22]</ref><ref type="bibr">[23]</ref><ref type="bibr" target="#b37">[24]</ref><ref type="bibr">[25]</ref><ref type="bibr">[26]</ref>. However, neither palmitoylation nor its related enzymes have been well-studied in OSCC.</p><p>Recently, ferroptosis has been found to be closely related to cancer progression <ref type="bibr">[27]</ref><ref type="bibr">[28]</ref><ref type="bibr">[29]</ref>. Ferroptosis is a newly identified non-apoptotic cell death caused by phospholipid peroxidation, which is named for its iron dependence <ref type="bibr">[27,</ref><ref type="bibr">28,</ref><ref type="bibr">[30]</ref><ref type="bibr">[31]</ref><ref type="bibr">[32]</ref>. The glutathione peroxidase 4 (GPX4) reduces phospholipid hydroperoxides to their corresponding alcohols and thus plays a key role in inhibiting ferroptosis <ref type="bibr">[23,</ref><ref type="bibr">[33]</ref><ref type="bibr">[34]</ref><ref type="bibr">[35]</ref><ref type="bibr" target="#b50">[36]</ref>. <ref type="bibr">Li et al.</ref> found that by increasing the stability of GPX4 and reducing intracellular reactive oxygen species (ROS), cysteine protease inhibitors inhibited ferroptosis and promoted migration and invasion of gastric cancer cells <ref type="bibr" target="#b52">[37]</ref>. <ref type="bibr">Cai and Green et al.</ref> reported that angiogenesis-related hypoxia-inducible factor (HIFs) instability or ablation can reduce the susceptibility of renal clear cell carcinoma and non-small cell lung cancer cells to ferroptosis, which revealed the interaction between ferroptosis and angiogenesis in cancer <ref type="bibr">[38,</ref><ref type="bibr">39]</ref>. However, the role and related mechanisms of ferroptosis in OSCC progression are not fully understood.</p><p>By bioinformatic analysis, a potential key role of palmitoylation related enzyme-PPT1 was found in OSCC. This study aimed to investigate the relationship between PPT1 expression level and the clinical features in OSCC patients, as well as the biological role of PPT1 in the regulation of proliferation, migration, invasion and ferroptosis of OSCC cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Differentially Expressed Genes Identification and Significant Genes Screening</head><p>The gene expression profiles of OSCC and normal tissues were downloaded from the NCBI Gene Expression Omnibus (NCBI-GEO) database (https://www.ncbi.nlm.nih.gov-/geo/query/acc.cgi?acc=GSE3524). Differentially expressed genes (DEGs) were screened out according to the cut-off criteria of P&lt;0.01 and fold change≥2. The false discovery rate (FDR) was used for correction. DEGs enrichment analyses were performed by the R package "clusterProfiler". To explore the significant genes in OSCC, the protein-protein interaction (PPI) pairs of DEGs were generated from the STRING database, and the criteria for PPI pairs were defined as a combined score≥0.4. DEGs related PPI network was built by Cytoscape software (version 3.9), and the Clus-terONE algorithm was performed for core gene screening, which was defined as quality&gt;0.60, node≥6, density&gt;0.05, combined score&gt;0.95 and P&lt;0.001.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Reconstruct the PPI Network and Identify the Core Targets</head><p>To identify novel therapeutic targets in OSCC, the selected significant genes were used to reconstruct the PPI network using the IntAct, IMEx, and iRefIndex databases. In the rebuilt network, four parameters of each node were calculated: Closeness Centrality (CC), Betweenness Centrality (BC), Topological Coefficient (TC) and Degree (De). Here, core targets defined as CC≥Avg (CC), BC≥Avg (BC), TC≥Avg (TC) and De≥Avg (De) were considered highly correlated with OSCC development.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Patients and Tissue Specimens</head><p>Patients diagnosed with OSCC in the Department of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital from Feb 2015 to Aug 2018, were enrolled in this study. All patients had no history of chemotherapy or radiotherapy. Clinic information and tumor samples were collected for further investigation. This study was approved by the Ethics Committee of Shanghai Ninth People's Hospital (Approval No: SH9H-2020-TK424-1). To explore the expression of PPT1, paraffin-embedded OSCC tissues were sectioned, deparaffinized, treated and scored as previously described <ref type="bibr" target="#b56">[40]</ref>. The sectioned tissues were incubated with anti-PPT1 primary antibody (1:400, Abcam) overnight at 4°C. The pathological score of each slide was determined by the formula: score=percentage score × staining intensity score. The staining intensity score was defined as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The percentage of positive cells was classified as 0 (0%), 1 (1%~25%), 2 (26%~50%), 3 (51%~75%) and 4 (&gt;75%). According to the pathological score, patients were grouped into negative expression group (0), weak expression group (1~3) and strong expression group (4~12). The correlation of PP-T1 expression levels with the clinic stage of the patients was analyzed. Age, gender, alcohol consumption, smoking, and tumor site were considered potential confounders in this study. To follow up on the survival, we contacted these patients in July 2023. The clinical characteristics of the patients are shown in Table <ref type="table" target="#tab_0">1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Cell Culture</head><p>Human OSCC cell lines-CAL-27, SCC-9 and WSU-H-N4 were used. CAL-27 (ATCC: CRL-2095) and SCC-9 (ATCC: CRL-1629) were obtained from Zhongyuan Biotech (Beijing, China). The Key Laboratory of Stomatology, Shanghai Ninth People's Hospital, kindly provided the WSU-HN4 cells. The complete culture medium for CAL-27 and WSU-HN4 was DMEM (Gibco, Rockville, MD, United States) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 μg/ml streptomycin (Beyotime, Shanghai, China) and 100 μg/ml penicillin (Beyotime). SCC-9 cells were cultured in DMEM/F12 (Gibco) supplemented with 10% FBS, 100 μg/ml streptomycin, 100 μg/ml penicillin and 400 Primary normal epithelial cells (NEC) were isolated from 5 normal oral mucosal tissues with no clinically visible inflammation, which was obtained from retained wisdom teeth extraction operations as described previously <ref type="bibr" target="#b58">[41,</ref><ref type="bibr" target="#b60">42]</ref>. The derived NECs were cultured in keratinocyte serum-free medium (KSF; Gibco) with 0.2 ng/mL recombinant epidermal growth factor (rEGF; Gibco).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Ferrous Ion and Malondialdehyde (MDA) Detection</head><p>Cells were treated with serum-free medium containing 1 µM FerroOrange (Dojindo, Japan) for 30 min at 37</p><p>• C in the dark. Then, the fluorescence of the cells was observed under the microscope (Axio Vert.A1, Carl Zeiss, Germany). RSL3 (an activator of ferroptosis, which binds and inactivates GPX4) was bought from MedChemExpress (Monmouth Junction, NJ, USA) and dissolved in DMSO (Beyotime). Cells were lysed, and concentrations of MDA were determined by the Lipid Peroxidation MDA Assay Kit (Beyotime) according to the manufacturer's instructions. The relative cellular MDA concentration was presented as a percentage of control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">RNA Extraction and Real-time PCR</head><p>The total RNA of OSCC cells and tissues was extracted by TRIzol reagent (Invitrogen, San Diego, CA, USA). Then, cDNA was obtained, and Real-time PCR was performed by using the PrimeScript™ RT reagent kit (TaKaRa, Shiga, Japan) and TB Green® Premix Ex Taq™ (TaKaRa) reaction system, respectively. Primer sequences were as followed. ppt1: sense 5'-CCCTGTAGATTCGGAGTGGT TTGG-3', antisense 5'-AGCTGTCCTGCATTGTCCAT TTCC-3'; gpx4: sense 5'-ATGGTTAACCTGGACAAGT ACC-3', antisense 5'-GACGAGCTGAGTGTAGTTTAC T-3'; gapdh: sense 5'-TCAAGGCTGAGAACGGGAAG-3', antisense 5'-TCGCCCCACTTGATTTTGGA-3'. GAPDH was used as an endogenous control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7.">Western Blotting Analysis</head><p>Total protein was extracted, quantified and denatured as described previously <ref type="bibr">[43]</ref>. Equal amounts of protein were loaded for electrophoresis and then electrophoretically transferred onto Polyvinylidene Difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). After blocking, the blots were incubated with different primary antibodies and Horseradish Peroxidase (HRP)-conjugated secondary antibodies. An imaging system visualized target bands. Anti-bodies against PPT1, E-cadherin, N-cadherin, and GAPDH were purchased from Abcam (Cambridge, USA). HRP-conjugated secondary antibodies were bought from ZSGB-Bio (Beijing, China).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.">Lentiviral Infection</head><p>Commercially available ppt1 overexpression lentiviral particles were obtained from GeneChem Biotech Co. (Shanghai, China) to establish cell lines with stable ppt1 overexpression. Lentivirus-based expression plasmid Ubi-MC-S-3FLAG-CBhgcGFP-IRES-puromycin constructs were used to carry ppt1 sequences. Primers for ppt1 were: forward 5'-CTCTAGAGGATCCCGCCACCATGGCGT CGC-CCGGCTGCCTG-3', reverse 5'-AGTCCATACCTC CAAGGAATGGTATGATGTGGGCATA-3'. To knockdown ppt1 expression, the short hairpin RNA (shRNA) targeting sequences for ppt1 were as follows: KD-PPT1-1: 5'-CCACATCATACCATTCCTT-3,' KD-PPT1-2: 5'-CA-TAAAGGAGGATGTGTAT-3,' and KD-PPT1-3: 5'--GATCCAGCTTGCAACTAAT-3'. Lentivirus-based expression plasmid hU6-MCS-CBh-gcGFP-IRES-puromycin constructs were used to carry shRNA sequences. To eliminate the influence of vector transfection, a gene sequence with no significant homology to any mammalian was transfected into the cells (OE-vector and KD-mock). The cells were transfected and cultured as previously described.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9.">Cell Proliferation and Transwell Assays</head><p>To determine cell viability, cells were plated into 96well plates and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Beyotime) was used. For the clonogenic assay, cells were plated in 6-well plates and cultured for 2 weeks. Crystal violet (Beyotime) was used to stain the colonies. To determine the proliferation of cells, the 5-ethynyl-2' -deoxyuridine (EdU, Beyotime) incorporation assay was performed according to the manufacturer's instructions. Cell nuclei were re-stained with Hoechst 33342 (Beyotime), and images were acquired using a fluorescence microscope. To determine cell migration and invasion, the Transwell assays were adopted as described previously <ref type="bibr" target="#b56">[40]</ref>. For cell invasion, Transwell inserts (Corning, New York, USA) were coated with Matrigel (BD Biosciences, San Jose, USA). The lower wells were added with a complete culture medium, while OSCC cells in the upper wells were suspended with DMEM. Cells passed through the membrane were stained with crystal violet solution and observed under a microscope.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10.">OSCC Cell Growth In Vivo</head><p>The animal experiment was approved by the Ethics Committee of Shanghai Ninth People's Hospital (Approval No: SH9H-2020-A729-1). Male BALB/c nude mice about four weeks old were bought from Shanghai Laboratory Animal Center (Shanghai, China) and kept in pathogen-free animal care facilities. OSCC cells were injected into the back next to the right hind limb of nude mice subcutaneously. Tumors were measured with a Vernier caliper every 3 days. Tumor volumes were calculated according to the following formula: tumor volume ( <ref type="formula">mm</ref>3 ) = longest diameter × shortest diameter 2 × 0.52. Once the growing tumor reached the predetermined size, the mice were euthanized, and tumors were separated and weighed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.11.">Statistical Analysis</head><p>Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, USA), and data were presented as mean ± SD. The relationship between PPT1 expression and patients' clinical features was analyzed with χ 2 test. Independent sample t-test was performed for the two groups, and one-way analysis of variance (ANOVA) was used among multiple groups. Sensitivity analysis was used to eliminate the interference caused by confounding factors, including gender, age, drinking, smoking, and tumor location. The overall survival rate was estimated using the Kaplan-Meier method and compared by the log-rank test. P&lt;0.05 was considered as statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Differentially Expressed Genes Identification and Significant Genes Screening</head><p>Using the cut-off criteria of FDR &lt; 0.001 and fold change &gt; 2, a total of 555 DEGs (212 upregulated and 323 downregulated genes) were screened between 16 OSCC tissues and four normal samples from GSE3524 (Fig. <ref type="figure" target="#fig_0">1A</ref>). The top 10 Biological Process (BP) terms revealed by Gene Ontology (GO) analysis were mainly associated with epidermal development, skin development, epidermal cell differentiation, regulation of epithelial cell proliferation, fatty acid metabolic processes, keratinocyte differentiation, keratinization, intermediate filament-based processes, intermediate filament cytoskeleton organization, and peptide cross-linking (Fig. <ref type="figure" target="#fig_0">1B</ref>). The top 10 Cellular Component (CC) terms were correlated with chromosomal regions, cornified envelopes, condensed chromosomes, ficolin-1-rich granules, tertiary granules, desmosomes, MHC class I protein complexes, mitotic checkpoint complexes, and epidermal lamellar bodies (Fig. <ref type="figure" target="#fig_0">1C</ref>). The top 10 Molecular Function (MF) terms included cadherin binding, protein serine/threonine kinase activity, ubiquitin-like protein ligase binding, protein serine kinase activity, structural constituents of the skin epidermis and cell adhesion mediator activity (Fig. <ref type="figure" target="#fig_0">1D</ref>). The top 10 terms derived from KEGG pathway analysis were mainly associated with cell cycle, lipid and atherosclerosis, cellular senescence, Kaposi sarcoma-associated herpes virus infection, MAPK signaling pathway, proteoglycans in cancer, human cytomegalovirus infection, Influenza A, Human immunodeficiency virus 1 infection, Epstein-Barr virus infection and Ras signaling pathway (Fig. <ref type="figure" target="#fig_0">1E</ref>).</p><p>To screen for significant genes in OSCC, DEGs related PPI network was constructed using the STRING database (Fig. <ref type="figure" target="#fig_0">1F</ref>). By performing the ClusterONE algorithm, 105 significant genes were isolated from the network, which were defined as quality&gt;0.60, node≥6, density&gt;0.05, combined score&gt;0.95 and P&lt;0.001 (Fig. <ref type="figure" target="#fig_0">1G</ref>). These genes may be important in the development of OSCC.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Reconstruct the PPI Network and Identify the Core Targets</head><p>To explore the core targets of OSCC, 105 significant genes were used to reconstruct the core PPI network using the IntAct, IMEx, and iRefIndex databases (Fig. <ref type="figure" target="#fig_1">2A</ref>). In the PPI network, core nodes were defined as BC ≥ avg (BC), CC ≥ avg (CC), De ≥ avg (De), and TC ≥ avg (TC). Finally, 6 core targets and related clusters were isolated from the PPI network (Fig. <ref type="figure" target="#fig_1">2B</ref>, Table <ref type="table" target="#tab_0">1</ref>), including CFTR (CF transmembrane conductance regulator), IFI16 (interferon-gamma inducible protein 16), GPX4, PPT1, FYN (FYN proto-oncogene, Src family tyrosine kinase), and FGFR3 (fibroblast growth factor receptor 3) clusters. To further identify novel therapeutic targets in OSCC, these six core clusters were merged (Fig. <ref type="figure" target="#fig_1">2C</ref>), and topological structure analysis revealed that the interacting PPT1 and GPX4 clusters played critical roles in the network (Fig. <ref type="figure" target="#fig_1">2D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">High Expression of PPT1 is Related to Poor Prognosis of OSCC</head><p>To further identify the results of bioinformatic analyses, PPT1 expression in 70 clinical specimens was determined first. The patients consisted of 51 males and 19 females. Information on ages, smoking status, alcohol use, tumor location, AJCC stages, T stages and N stages of the patients was listed in Table <ref type="table" target="#tab_1">2</ref>. Significantly higher PPT1 expression in OSCC tissues than in adjacent normal tissues was found both by qRT-PCR and western blotting (Fig. <ref type="figure" target="#fig_2">3A</ref> and<ref type="figure" target="#fig_2">3B</ref>). 81.42% (57/70) cases had positive staining for PPT1, of which 57.89% (33/57) showed high expression and 42.11% (24/57) showed low expression (Fig. <ref type="figure" target="#fig_2">3C,</ref><ref type="figure" target="#fig_1">Table 2</ref>). A significant association was observed between PPT1 expression with the clinic stages of OSCC patients (AJCC stage, P=0.014; T stage, P=0.005; N stage, P=0.013) (Table <ref type="table" target="#tab_1">2</ref>). Moreover, OSCC patients with higher PPT1 expression levels exhibited lower overall survival rate, with 16 cases developing tumor progression and 11 of them having high expression of PPT1 (Fig. <ref type="figure" target="#fig_2">3D</ref>). These data indicated that PPT1was positively correlated with the undesirable clinical characteristics in OSCC.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">PPT1 Facilitates the Proliferation and Metastasis of OSCC Cells In Vitro</head><p>To confirm the pro-tumor effect of PPT1 in OSCC, OSCC cell lines were used. PPT1 expression in OSCC cells </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</head><p>was significantly increased (Fig. <ref type="figure" target="#fig_3">4A</ref> and<ref type="figure" target="#fig_3">4B</ref>). Next, we established the PPT1 overexpression or knockdown cell lines using CAL-27. PPT1 expression was significantly increased in OE-PPT1 cells, and shRNA targeting sequence 3 (KD-PP-T1-3) transfection showed the most potent knockdown effect, with a 25.14-fold decrease in mRNA expression (Fig. <ref type="figure" target="#fig_3">4C</ref> and<ref type="figure" target="#fig_3">4D</ref>). Thus, we used KD-PPT1-3 cells for subsequent experiments. Results indicated that PPT1 overexpression significantly increased the proliferation, colony formation, and EdU incorporation of OSCC cells, whereas the knockdown of PPT1 led to the opposite effects (Fig. <ref type="figure" target="#fig_3">4E-I</ref>). PPT1 overexpression also facilitated the migration and invasion of OSCC cells (Fig. <ref type="figure" target="#fig_3">4J</ref>). Epithelial-mesenchymal transition (EMT)-related proteins were further identified. Consistently, the mesenchymal marker N-cadherin was increased, whereas the epithelial adhesion marker E-cadherin was decreased in PP-T1-overexpressed OSCC cells (Fig. <ref type="figure" target="#fig_3">4K</ref>). In OSCC cells with PPT1 knockdown, the opposite phenomenon was observed (Fig. <ref type="figure" target="#fig_3">4K</ref>). Thus, these results suggested that PPT1 facilitated the proliferation and metastasis of OSCC cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">PPT1 Enhances the Growth of OSCC Cells In Vivo</head><p>To explore the effect of PPT1 on OSCC cell growth in vivo, the OSCC xenograft mouse model was used. OSCC cells overexpressing PPT1 overexpression (OE-PPT1), knockdown (KD-PPT1-3), or mock vector (OE-vector and KD-mock) were injected subcutaneously into mice as described in materials and methods. Increased tumor size was observed in tumors from the PPT1 overexpression group, whereas distinctly reduced tumor size was found in the PP-T1 knockdown group (Fig. <ref type="figure" target="#fig_4">5A</ref> and<ref type="figure" target="#fig_4">5B</ref>). Similar patterns were observed in the tumor weights of different groups (Fig. <ref type="figure" target="#fig_4">5C</ref>). These data showed that PPT1 enhanced the growth of OSCC cells in vivo.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">PPT1 Impairs Ferroptosis via Regulating GPX4 Expression</head><p>As a newly discovered form of non-apoptotic programmed cell death, ferroptosis has been a focus of research in a variety of diseases, including cancer <ref type="bibr">[43]</ref>. GPX4 is a </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</head><p>well-known ferroptosis inhibitory factor <ref type="bibr" target="#b62">[44]</ref>. Topological structural analysis indicated that the core clusters of PPT1 and GPX4 interacted (Fig. <ref type="figure" target="#fig_1">2D</ref>), suggesting a potential effect of PPT1 on ferroptosis. In our study, a positive correlation between PPT1 and GPX4 mRNA expression was observed in OSCC tissues (r=0.3690, P=0.0268; Fig. <ref type="figure" target="#fig_5">6A</ref>). Moreover, overexpression of PPT1 markedly increased the expression of GPX4 in OSCC cells, whereas PPT1 knockdown significantly decreased GPX4 expression (Fig. <ref type="figure" target="#fig_5">6B</ref> and<ref type="figure" target="#fig_5">6C</ref>). With the FerroOrange (a specific probe for Fe 2+ ), we found the intracellular red fluorescence signal was significantly enhanced in PPT1 knockdown cells (which indicated an increase of intracellular Fe 2+ level) and obviously decreased in PPT1-overexpressed cells (Fig. <ref type="figure" target="#fig_5">6D</ref>). Accordingly, MDA level, an indicator of lipid oxidation, was reduced in PPT1-overexpressed OSCC cells and increased in PPT1 knockdown cells (Fig. <ref type="figure" target="#fig_5">6E</ref>). Sensitivities to the ferroptosis-inducer RS-L-3 (an inhibitor of GPX4) were compromised in OSCC cells with PPT1 overexpression, but enhanced in PPT1 knockdown cells (Fig. <ref type="figure" target="#fig_5">6F</ref>). Thus, we inferred that PPT1 impaired ferroptosis in OSCC cells via regulating GPX4 expression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">DISCUSSION</head><p>Our previous study revealed that PPT1 reduction contributed to erianin-induced growth inhibition in OSCC <ref type="bibr">[45]</ref>, which preliminarily revealed the pro-OSCC growth effect of PPT1. However, the underlying molecular mechanisms of PPT1 in OSCC have not been well elucidated. Here, we demonstrate for the first time that PPT1 expression correlates with tumor size, lymphatic metastasis, and the prognosis of OSCC patients. PPT1 obviously promotes the growth of OSCC cells and reduces their sensitivity to ferroptosis via GPX4.  Note: **Former/current smokers were defined as having at least a one-pack-year history of smoking; ***Alcohol intake was defined as current alcohol intake of more than one drink per day for 1 year. Others were classified as having no alcohol intake; *P-values are based on chi-squared or Fisher's exact test. P&lt;0.05 indicates a significant association among the variables.  OSCC accounts for up to 90% of all malignant head and neck malignant neoplasms <ref type="bibr">[1]</ref><ref type="bibr" target="#b2">[2]</ref><ref type="bibr" target="#b4">[3]</ref><ref type="bibr" target="#b65">46]</ref>. Despite recent advances in cancer research and therapy, the prognosis of OSCC has not significantly improved, which has posed a persistent challenge in the biomedical field. Although OSCC is not featured among the top cancers in either China or worldwide <ref type="bibr" target="#b2">[2]</ref>, OSCC also suffers a lot in terms of quality of life, financial burden, and mental stress as other cancer patients. Therefore, further understanding of the underlying mechanisms that drive its progression and identifying more potent therapeutic targets is of great importance. We got 555 DEGs of OSCC from the GEO database and isolated 105 significant genes from the PPI network. Furthermore, these 105 significant genes were used to reconstruct the PPI network and six core target-related clusters were selected, including CFTR, IFI16, GPX4, PPT1, FYN, and FGFR3 clusters. As the topological structure analysis suggested an interaction of the kernel clusters of PPT1 and GPX4, which indicates a potential innovative link between palmitoylation and ferroptosis, we focused on these two items in this study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>001).). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</head><p>Palmitoylation, a newly identified form of posttranslational protein modification, has been shown to play critical roles in cancer progression, including tumor cell proliferation <ref type="bibr">[28]</ref>, adhesion <ref type="bibr">[47]</ref>, migration <ref type="bibr" target="#b68">[48]</ref>, metastasis <ref type="bibr">[49]</ref> and apoptosis <ref type="bibr" target="#b71">[50]</ref> etc. The aberrant expression of palmitoylation-and depalmitoylation-related enzymes has been reported in various cancers <ref type="bibr">[18]</ref>. <ref type="bibr">Yuan et al.</ref> found that deprivation of ZDHHC12-mediated palmitoylation of the membrane protein claudin-3 significantly abolished the tumorigenic promotion effect of claudin-3 in ovarian cancer cells <ref type="bibr" target="#b73">[51]</ref>. <ref type="bibr">Kwon et al.</ref> demonstrated that APT-1 catalyzed flotillin-1 depalmitoylation, and ZDHHC-19 mediated the repalmitoylation of flotillin-1 for its turnover in cervical cancer cells. The turnover prevented desensitization of insulin-like growth factor-1 receptor (IGF-1R) via endocytosis and lysosomal degradation, thereby causing excessive IGF-1R activation in cervical cancer cells <ref type="bibr">[52]</ref>. PPT1, which deacylates the palmitoylated proteins in lysosomes, has been reported to be a promising therapeutic target for melanoma and HCC. Amaravadi et al. found that increased PPT1 expression was associated with poor survival in melanoma <ref type="bibr">[25]</ref>. Genetic suppression of PPT1 led to impaired autophagic flux and affected cell growth by the disrupted lysosomal localization of mTOR and inhibited lysosomal catabolism <ref type="bibr">[25]</ref>. Moreover, PPT1 inhibition induced the activation of the cyclic GMP-AMP synthase (cGAS) /stimulator of interferon genes (STING) /TANK binding kinase 1 (TBK1) pathway and secretion of interferon-β in macrophages, which is critical for the augmentation of T cell-mediated cytotoxicity <ref type="bibr" target="#b76">[53]</ref>. Zheng et al. reported that high PPT1 expression predicted poor clinical outcomes and that the PPT1 inhibitor DC661 enhanced sorafenib sensitivity in HCC <ref type="bibr" target="#b78">[54]</ref>. In our study, bioinformatics analysis suggested the potential importance of PPT1 in OSCC development. Higher PPT1 expression was identified in OSCC tissues, which was associated with worse prognosis of the patients. Further investigation indicated that PPT1 expression correlated with the AJCC, T, and N stages of OSCC patients. Moreover, we found that PP-T1 promoted proliferation and metastasis of OSCC cells and enhanced the growth of OSCC cells in vivo. Thus, these data confirmed the pro-tumor effect of PPT1 in OSCC.</p><p>Previous studies on PPT1 in melanoma and HCC have uncovered the importance of PPT1 in the activation of mTOR signaling and autophagy <ref type="bibr" target="#b37">[24,</ref><ref type="bibr">25]</ref>. Usually, mTOR moves to approach its activator RHEB on the lysosomal surface, and this process is regulated by the v-ATPase and Ragulator machinery <ref type="bibr">[55]</ref>. PPT1 inhibition causes mislocalization of v-ATPase, subsequently leading to the inhibition of mTOR signaling and blockade of autophagic flux due to lysosomal deacidification <ref type="bibr">[25]</ref>. Consistent results were observed in OSCC cells in our previous study <ref type="bibr">[45]</ref>. Thus, we did not further examine mTOR signaling and autophagy-related proteins here. As increasing evidence indicates that lysosomes regulate iron metabolism to ensure ferroptosis <ref type="bibr" target="#b81">[56,</ref><ref type="bibr">57]</ref>, and the interaction between PPT1 and GPX4 was indicated by topological structure analysis, we further explored whether there was any relationship between PPT1 and ferroptosis in OSCC. Interestingly, we found that the expres- sion levels of GPX4 and PPT1 were positively correlated in OSCC tissues. Overexpression of PPT1 increased GPX4 expression in OSCC cells, whereas PPT1 knockdown decreased GPX4 expression. With the FerroOrange probe, we found intracellular Fe 2+ level was significantly increased in PPT1 knockdown cells while obviously decreased in PP-T1-overexpressed cells. Accordingly, lipid oxidation, as indicated by MDA levels, was decreased in PPT1-overexpressed OSCC cells and increased in PPT1-knockdown cells. As a distinctly vital enzyme for converting phospholipid hydroperoxides in membranes to non-toxic alcohols, GPX4 is considered and has been proven to be critical in regulating ferroptosis in diseases <ref type="bibr">[33]</ref><ref type="bibr">[34]</ref><ref type="bibr">[35]</ref><ref type="bibr" target="#b50">[36]</ref><ref type="bibr" target="#b84">[58]</ref><ref type="bibr" target="#b86">[59]</ref><ref type="bibr">[60]</ref><ref type="bibr" target="#b89">[61]</ref><ref type="bibr" target="#b91">[62]</ref>. Various shreds of evidence show that targeting GPX4-induced ferroptosis is a promising strategy for disease therapy. Deng et al. reported that quercetin alleviated LPS-induced acute lung injury by inhibiting ferroptosis via the Sirt1/Nrf2/Gpx4 signaling pathway <ref type="bibr" target="#b84">[58]</ref>. <ref type="bibr">Baruah et al.</ref> showed tannic acid-activated and enhanced GPX4 to mitigate amyloid-β induced ferroptosis in treating Alzheimer's disease <ref type="bibr" target="#b93">[63]</ref>. Akiyama et al. found GPX4 knockdown-induced ferroptosis in acute myeloid leukemia (AML) cells, exerting anti-AML effects in vitro and in vivo <ref type="bibr" target="#b86">[59]</ref>. Xu et al. demonstrated the inactivation of GPX4 in tamoxifen-resistant breast cancer cells resensitized the cells to tamoxifen by increasing ferroptosis-mediated cell death <ref type="bibr" target="#b95">[64]</ref>. Therefore, based on the literature reports of GPX4 in ferroptosis and our findings, we inferred that PPT1 inhibited ferroptosis in OSCC cells by modulating GPX4 expression.</p><p>In our study, we observed the pro-tumor growth effect of PPT1 in OSCC. However, there were limitations. First, in evaluating the effect of PPT1 on the overall survival rate, we did not exclude the potential interference of other diseases like diabetes, hypertension etc. and other therapies like Chinese herbs, various drug intakes etc. More patients and more rigorous experimental design are warranted. What's more, detailed mechanisms underlying the regulation of PPT1 on GPX4 need further investigation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p>In summary, we obtained 555 DEGs between OSCC and normal oral epithelial tissues using the NCBI GEO database. By constructing the PPI network and topological analysis, we found that PPT1 and GPX4 might play critical roles in OSCC. Further investigation identified significantly increased PPT1 expression in OSCC tissues, which was correlated with tumor size, clinic stages and prognosis of OSCC patients. Moreover, PPT1 effectively promotes growth while inhibiting ferroptosis in OSCC cells. Thus, PPT1 may be a potential therapeutic target for OSCC. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LIST OF ABBREVIATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OSCC</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ETHICS APPROVAL AND CONSENT TO PARTICI-PATE</head><p>The study was approved by the Ethics Committee of Shanghai Ninth People's Hospital.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HUMAN AND ANIMAL RIGHTS</head><p>The animal experiments were performed in strict accordance with the institutional guidelines for the use of laboratory animals (The Ministry of Science and Technology of <ref type="bibr">China, 2006)</ref> and followed ARRIVE guidelines.</p><p>All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional and/or research committees and with the 1975 Declaration of Helsinki, as revised in 2013.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONSENT FOR PUBLICATION</head><p>All of the patients provided their written informed consent for us to obtain the clinical samples.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>STANDARDS OF REPORTING</head><p>STROBE guidelines were followed.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. ( 1</head><label>1</label><figDesc>Fig. (1). OSCC-related DEGs analysis and significant genes screening. (A) Differentially expressed genes of OSCC were calculated based on the GSE3524 dataset. (B) The top 10 BP terms of the DEGs from GO analysis. (C) The top 10 CC terms of the DEGs from GO analysis. (D) The top 10 MF terms of the DEGs from GO analysis. (E) KEGG pathway analysis of the DEGs. (F) The DEGs-related PPI network construction based on STRING database. (G) The significant genes screened from PPI network.). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="5,61.70,68.03,488.59,345.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. ( 2 )</head><label>2</label><figDesc>Fig. (2). The core PPI network construction and core targets screening. (A) The core PPI network was reconstructed based on the 105 significant genes. (B) The 6 core targets and related clusters were isolated from the PPI network. (C) The 6 core clusters were merged to rebuild the PPI network. (D) The PPT1-GPX4 clusters isolated from the network.). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="6,60.41,68.03,491.19,390.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. ( 3</head><label>3</label><figDesc>Fig. (3). PPT1 expression was increased in OSCC tissues. (A) PPT1 mRNA expression. (B) PPT1 protein expression. (C) IHC staining of PP-T1 in tissues (magnification 100x). (D) Correlation of PPT1 expression with OSCC patients' overall survival rate. (***P&lt;0.001).). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="7,51.02,68.03,509.95,295.48" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. ( 4 )</head><label>4</label><figDesc>Fig. (4). PPT1 facilitated the proliferation and metastasis of OSCC cells. (A) PPT1 mRNA expression in OSCC cell lines and normal epithelial cells (NEC). (B) PPT1 protein expression in different cell lines. (C) PPT1 mRNA and (D) protein expression in lentivirus particles transfected CAL-27 cells. (E) Viabilities of CAL-27 cells with lentivirus transfection. (F-G) Colony formation of different CLA-27 cells. (H) EdU incorporation in different CLA-27 cells. (I) Ratio of EdU incorporated cells in each group. (J) Representative images of the Transwell assays. (K) Western blotting bands of EMT-related proteins. Results are representative of three experiments. (*P&lt;0.05, **P&lt;0.01, ***P&lt;0.001; magnification, 100×).). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="8,51.02,270.49,509.95,356.83" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. ( 5 )</head><label>5</label><figDesc>Fig. (5). PPT1 enhanced OSCC cell growth in vivo. The OSCC xenograft mice models were established with different CAL-27 cells. (A) Tumor volumes. (B) Representative tumor images. (C) Tumor weights. Each group included five mice. Data are representative of three experiments. (**P&lt;0.01, ***P&lt;0.001).). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="9,51.02,68.03,509.95,156.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. ( 6</head><label>6</label><figDesc>Fig. (6). PPT1 impaired ferroptosis via regulating GPX4 expression. (A) The mRNA expression of PPT1 and GPX4 was positively correlated in OSCC tissues. (B) GPX4 expression in CAL-27 cells with or without changed PPT1 expression was determined at the mRNA level. (C) GPX4 expression in different cells at the protein level. (D) Fluorescence images of intracellular Fe 2+ determined by the FerroOrange probe (magnification 200x). (E) Relative MDA percentage in different OSCC cells. (F) Cell viabilities of OSCC cells treated with different concentrations of RSL-3 for 72h. Results are representative of three experiments. (*P &lt; 0.05, **P &lt; 0.01). (A higher resolution / colour version of this figure is available in the electronic copy of the article).</figDesc><graphic coords="10,51.02,68.03,509.95,487.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . The parameters distribution of core genes of OSCC.</head><label>1</label><figDesc></figDesc><table><row><cell>Kernel Targets</cell><cell>Betweenness Centrality</cell><cell>Closeness Centrality</cell><cell>Degree</cell><cell>Topological Coefficient</cell></row><row><cell>CFTR</cell><cell>0.050314</cell><cell>0.412286</cell><cell>48</cell><cell>0.0366301</cell></row><row><cell>IFI16</cell><cell>0.030026</cell><cell>0.332952</cell><cell>170</cell><cell>0.0275163</cell></row><row><cell>GPX4</cell><cell>0.024919</cell><cell>0.318663</cell><cell>69</cell><cell>0.0196425</cell></row><row><cell>PPT1</cell><cell>0.060778</cell><cell>0.349769</cell><cell>224</cell><cell>0.0152344</cell></row><row><cell>FYN</cell><cell>0.042413</cell><cell>0.353132</cell><cell>213</cell><cell>0.0144149</cell></row><row><cell>FGFR3</cell><cell>0.037012</cell><cell>0.358169</cell><cell>170</cell><cell>0.0133465</cell></row><row><cell cols="3">ng/ml hydrocortisone (Sigma-Aldrich, St. Louis, MI, USA).</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Correlation of PPT1 expression with clinic characteristics of OSCC patients. Characteristics n (70) PPT1 Expression P-value Negative (13) Weak (24) Positive (33)</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell></cell></row><row><cell>Age (years)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.891</cell></row><row><cell>≤60</cell><cell>39</cell><cell>8 (20.5)</cell><cell>13 (33.3)</cell><cell>18 (46.2)</cell><cell>-</cell></row><row><cell>&gt;60</cell><cell>31</cell><cell>5 (16.1)</cell><cell>11 (35.5)</cell><cell>15 (48.4)</cell><cell>-</cell></row><row><cell>Sex</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.221</cell></row><row><cell>male</cell><cell>51</cell><cell>7 (13.7)</cell><cell>18 (35.3)</cell><cell>26 (51.0)</cell><cell></cell></row><row><cell>female</cell><cell>19</cell><cell>6 (25)</cell><cell>6 (25)</cell><cell>7 (50)</cell><cell></cell></row><row><cell>Smoking status</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.780</cell></row><row><cell>current/former</cell><cell>33</cell><cell>5 (15.2)</cell><cell>12 (36.4)</cell><cell>16 (48.5)</cell><cell>-</cell></row><row><cell>never</cell><cell>37</cell><cell>8 (21.6)</cell><cell>12 (32.4)</cell><cell>17 (45.9)</cell><cell>-</cell></row><row><cell>Alcohol use</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.374</cell></row><row><cell>yes</cell><cell>21</cell><cell>2 (4.8)</cell><cell>9 (42.9)</cell><cell>10 (47.6)</cell><cell>-</cell></row><row><cell>no</cell><cell>49</cell><cell>11 (22.4)</cell><cell>15 (30.6)</cell><cell>23 (46.9)</cell><cell>-</cell></row><row><cell>Location</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.365</cell></row><row><cell>gingiva</cell><cell>20</cell><cell>5 (25.0)</cell><cell>5 (25.0)</cell><cell>10 (50.0)</cell><cell>-</cell></row><row><cell>tongue</cell><cell>28</cell><cell>5 (17.9)</cell><cell>12 (42.9)</cell><cell>11 (39.2)</cell><cell>-</cell></row><row><cell>floor of mouth</cell><cell>13</cell><cell>2 (15.4)</cell><cell>2 (15.4)</cell><cell>9 (69.2)</cell><cell>-</cell></row><row><cell>buccal</cell><cell>9</cell><cell>1 (11.1)</cell><cell>5 (55.6)</cell><cell>3 (33.3)</cell><cell>-</cell></row><row><cell>AJCC stage</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>0.014*</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2" xml:id="foot_0"><p>Current Cancer Drug Targets, XXXX, Vol. XX, No. XX Luo et al.</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="4" xml:id="foot_1"><p>Current Cancer Drug Targets, XXXX, Vol. XX, No. XX Luo et al.</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>ACKNOWLEDGEMENTS</head><p>We would like to thank the <rs type="institution">Key Laboratory of Stomatology, Shanghai Ninth People's Hospital</rs>, for providing OSCC cell lines.</p></div>
			</div>
			<div type="funding">
<div><head>FUNDING</head><p>This work was supported by the <rs type="funder">Shanghai Municipal Natural Science Foundation</rs> (Grant no. <rs type="grantNumber">20ZR1431500</rs>).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_YW3DcDV">
					<idno type="grant-number">20ZR1431500</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AVAILABILITY OF DATA AND MATERIALS</head><p>All of the data included in this study are available from the corresponding author (Dr. Chen) or first author (Dr. Luo) upon reasonable request.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p>The authors declare no conflict of interest, financial or otherwise.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCLAIMER:</head><p>The above article has been published, as is, ahead-of-print, to provide early visibility but is not the final version. Major publication processes like copyediting, proofing, typesetting and further review are still to be done and may lead to changes in the final published version, if it is eventually published. All legal disclaimers that apply to the final published article also apply to this ahead-of-print version.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Head and neck cancer</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Q M</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMra1715715</idno>
		<idno type="PMID">31893516</idno>
		<ptr target="http://dx.doi.org/10.1056/NEJMra1715715" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="60" to="72" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laversanne</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Soerjoma-</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</title>
		<author>
			<persName><forename type="first">I</forename><surname>Taram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21660</idno>
		<idno type="PMID">33538338</idno>
		<ptr target="http://dx.doi.org/10.3322/caac.21660" />
	</analytic>
	<monogr>
		<title level="j">CA Cancer J. Clin</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="209" to="249" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Y</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Nice</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Oral squamous cell carcinomas: State of the field and emerging directions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41368-023-00249-w</idno>
		<ptr target="http://dx.doi.org/10.1038/s41368-023-00249-wPMID" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Oral Sci</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">37736748</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Nokovitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Maquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Crampon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Taihi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Roussel</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Oral cavity squamous cell carcinoma risk factors: State of the art</title>
		<author>
			<persName><forename type="first">R</forename><surname>Obongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Virard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fervers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Deneuve</surname></persName>
		</author>
		<idno type="DOI">10.3390/jcm12093264</idno>
		<idno type="PMID">37176704</idno>
		<ptr target="http://dx.doi.org/10.3390/jcm12093264" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">3264</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Badwelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Muaddi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Tran</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Oral squamous cell carcinoma and concomitant primary tumors, what do we know? A review of the literature</title>
		<idno type="DOI">10.3390/curroncol30040283</idno>
		<idno type="PMID">37185396</idno>
		<ptr target="http://dx.doi.org/10.3390/curroncol30040283" />
	</analytic>
	<monogr>
		<title level="j">Curr. Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3721" to="3734" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Tobacco use and oral health</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<idno type="DOI">10.1111/add.15513</idno>
		<idno type="PMID">33822437</idno>
		<ptr target="http://dx.doi.org/10.1111/add.15513" />
		<imprint>
			<date type="published" when="2021">2021</date>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="3531" to="3540" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Imbesi Bellantoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Picciolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pirrotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Irrera</surname></persName>
		</author>
		<imprint>
			<pubPlace>Vac-</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Oral cavity squamous cell carcinoma: An update of the pharmacological treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Caro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vaccaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Squadrito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pallio</surname></persName>
		</author>
		<idno type="DOI">10.3390/biomedicines11041112</idno>
		<idno type="PMID">37189730</idno>
		<ptr target="http://dx.doi.org/10.3390/biomedicines11041112" />
	</analytic>
	<monogr>
		<title level="j">Biomedicines</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">1112</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">I</forename><surname>Dewenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kumbrink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Poxleitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Smolka</surname></persName>
		</author>
		<author>
			<persName><surname>Liokatis</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">New insights into redox-related risk factors and therapeutic targets in oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fliefel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Obermeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.oraloncology.2023.106573</idno>
		<idno type="PMID">37951115</idno>
		<ptr target="http://dx.doi.org/10.1016/j.oraloncology.2023.106573" />
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page">106573</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Biswal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Panda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Sahoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Tripathi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Biswal</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer</title>
		<idno type="DOI">10.1016/j.archoralbio.2023.105697</idno>
		<idno type="PMID">37079976</idno>
		<ptr target="http://dx.doi.org/10.1016/j.archoralbio.2023.105697" />
	</analytic>
	<monogr>
		<title level="j">Arch. Oral Biol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page">105697</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The roles of exosomes in the diagnose, de-[10] velopment and therapeutic resistance of oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">L</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jia</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms24031968</idno>
		<idno type="PMID">36768288</idno>
		<ptr target="http://dx.doi.org/10.3390/ijms24031968" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="1968">2023. 1968</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C A</forename><surname>Caponio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhurakivska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lo Muzio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Troiano</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Cir-</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The immune cells in the development of oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<idno type="DOI">10.3390/cancers15153779</idno>
		<idno type="PMID">37568595</idno>
		<ptr target="http://dx.doi.org/10.3390/cancers15153779" />
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page">3779</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Hallmarks of cancer: New dimensions</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hanahan</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-21-1059</idno>
		<idno type="PMID">35022204</idno>
		<ptr target="http://dx.doi.org/10.1158/2159-8290.CD-21-1059" />
		<imprint>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="31" to="46" />
		</imprint>
	</monogr>
	<note>Cancer Dis-[12] cov.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Small-molecule modulation of protein lipidation: From chemical probes to therapeutics</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1002/cbic.202300071</idno>
		<idno type="PMID">37059689</idno>
		<ptr target="http://dx.doi.org/10.1002/cbic.202300071" />
	</analytic>
	<monogr>
		<title level="j">ChemBioChem</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">14</biblScope>
			<date type="published" when="2023">2023. 202300071</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Unraveling the post-translational modifica-[14] tions and therapeutical approach in NSCLC pathogenesis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gulhane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tranon.2023.101673</idno>
		<idno type="PMID">37062237</idno>
		<ptr target="http://dx.doi.org/10.1016/j.tranon.2023.101673" />
	</analytic>
	<monogr>
		<title level="j">Transl. Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">101673</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Pathological implication of protein post-transla</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chen</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">tional modifications in cancer</title>
		<idno type="DOI">10.1016/j.mam.2022.101097</idno>
		<idno type="PMID">35400524</idno>
		<ptr target="http://dx.doi.org/10.1016/j.mam.2022.101097" />
	</analytic>
	<monogr>
		<title level="j">Mol. Aspects Med</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page">101097</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<author>
			<persName><forename type="first">G</forename><surname>Heieis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Everts</surname></persName>
		</author>
		<author>
			<persName><surname>O-</surname></persName>
		</author>
		<title level="m">GlcNAcylation at the center of antitu</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title/>
		<author>
			<orgName type="collaboration">mor immunity</orgName>
		</author>
		<idno type="DOI">10.1016/j.copbio.2023.103009</idno>
		<idno type="PMID">37863017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.copbio.2023.103009" />
	</analytic>
	<monogr>
		<title level="j">Curr. Opin. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page">103009</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Targeting protein modifications in metabolic diseases: Molecular mechanisms and targeted therapies</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Geng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Weng</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-023-01439-y</idno>
		<idno type="PMID">37244925</idno>
		<ptr target="http://dx.doi.org/10.1038/s41392-023-01439-y" />
	</analytic>
	<monogr>
		<title level="j">Signal Transduct. Target. Ther</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">220</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Protein palmitoylation in [18] cancer: molecular functions and therapeutic potential</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kong</surname></persName>
		</author>
		<idno type="DOI">10.1002/1878-0261.13308</idno>
		<idno type="PMID">36018061</idno>
		<ptr target="http://dx.doi.org/10.1002/1878-0261.13308" />
	</analytic>
	<monogr>
		<title level="j">Mol. Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="26" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<author>
			<persName><forename type="first">M</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<title level="m">Lipid-induced S-palmitoyla</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">tion as a Vital Regulator of Cell Signaling and Disease Development</title>
		<idno type="DOI">10.7150/ijbs.64046</idno>
		<idno type="PMID">34803494</idno>
		<ptr target="http://dx.doi.org/10.7150/ijbs.64046" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Biol. Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="4223" to="4237" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<author>
			<persName><forename type="first">J</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><surname>Wang</surname></persName>
		</author>
		<title level="m">L. S-palmitoylation regulates innate im</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">mune signaling pathways: Molecular mechanisms and targeted therapies</title>
		<idno type="DOI">10.1002/eji.202350476</idno>
		<idno type="PMID">37369620</idno>
		<ptr target="http://dx.doi.org/10.1002/eji.202350476" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">2350476</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Mechanisms [21] regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41571-022-00601-9</idno>
		<idno type="PMID">35132224</idno>
		<ptr target="http://dx.doi.org/10.1038/s41571-022-00601-9" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="287" to="305" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Mechanisms for regulation of RAS palmitoyla-[22] tion and plasma membrane trafficking in hematopoietic malignancies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qian</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI171104</idno>
		<idno type="PMID">37317974</idno>
		<ptr target="http://dx.doi.org/10.1172/JCI171104" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">171104</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><forename type="middle">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.72244</idno>
		<idno type="PMID">35637973</idno>
		<ptr target="http://dx.doi.org/10.7150/ijbs.72244" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Biol. Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="3447" to="3457" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Brun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bestion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bassissi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Jilkova</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mezouar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rachid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Novello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tracz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hamaï</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lalmanach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vanderlynden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Legouffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stauber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Plach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Courcambeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Drouot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jacquemot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Serdjebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Baudoin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ansaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Decaens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Halfon</surname></persName>
		</author>
		<idno type="DOI">10.1080/15548627.2021.1988357</idno>
		<idno type="PMID">34740311</idno>
		<ptr target="http://dx.doi.org/10.1080/15548627.2021.1988357" />
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="678" to="694" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Rebecca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Nicastri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fennelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Chude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Rotenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ronghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mcafee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Mclaughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ojha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Piao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Noguera-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martorella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Alicea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Schuchter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Herlyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marmorstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gimotty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Speicher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Amaravadi</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-18-0706</idno>
		<idno type="PMID">30442709</idno>
		<ptr target="http://dx.doi.org/10.1158/2159-8290.CD-18-0706" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="220" to="229" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ojha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Noguera-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Rebecca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Attana ; Sio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Piao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Nicastri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ronghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Speicher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mastio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gimotty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Wherry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Gabrilovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Amaravadi</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci.insight.165688</idno>
		<idno type="PMID">36278493</idno>
		<ptr target="http://dx.doi.org/10.1172/jci.insight.165688" />
	</analytic>
	<monogr>
		<title level="j">JCI Insight</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page">165688</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Ferroptosis: Mechanisms, [27] biology and role in disease</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Stockwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Conrad</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41580-020-00324-8</idno>
		<ptr target="http://dx.doi.org/10.1038/s41580-020-00324-8PMID" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Mol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">33495651</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Fer-[28] roptosis in cancer progression</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.3390/cells12141820</idno>
		<idno type="PMID">37508485</idno>
		<ptr target="http://dx.doi.org/10.3390/cells12141820" />
	</analytic>
	<monogr>
		<title level="j">Cells</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page">1820</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Targeting ferropto-[29] sis pathways: A novel strategy for cancer therapy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Maru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hothi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bagariya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
		<idno type="DOI">10.2174/1568009622666220211122745</idno>
		<idno type="PMID">35152865</idno>
		<ptr target="http://dx.doi.org/10.2174/1568009622666220211122745" />
	</analytic>
	<monogr>
		<title level="j">Curr. Cancer Drug Targets</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="234" to="244" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Oxytosis/fer-[30] roptosis in neurodegeneration: The underlying role of master regulator glutathione peroxidase 4 (GPX4)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Dar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bhat</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12035-023-03646-8</idno>
		<idno type="PMID">37725216</idno>
		<ptr target="http://dx.doi.org/10.1007/s12035-023-03646-8" />
	</analytic>
	<monogr>
		<title level="j">Mol. Neurobiol</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Ferroptosis turns 10: Emerging mechanisms, phy-[31] siological functions, and therapeutic applications</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Stockwell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2022.06.003</idno>
		<idno type="PMID">35803244</idno>
		<ptr target="http://dx.doi.org/10.1016/j.cell.2022.06.003" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="2401" to="2421" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The therapeutic potential of targeting [32] regulated non-apoptotic cell death</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hadian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Stockwell</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41573-023-00749-8</idno>
		<ptr target="http://dx.doi.org/10.1038/s41573-023-00749-8PMID" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discov</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">37550363</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Targeting GPX4 in human cancer: Implications [33] of ferroptosis induction for tackling cancer resilience</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Roh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2023.216119</idno>
		<idno type="PMID">36893895</idno>
		<ptr target="http://dx.doi.org/10.1016/j.canlet.2023.216119" />
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">559</biblScope>
			<biblScope unit="page">216119</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">GPX4: The [34] hub of lipid oxidation, ferroptosis, disease and treatment</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbcan.2023.188890</idno>
		<idno type="PMID">37001616</idno>
		<ptr target="http://dx.doi.org/10.1016/j.bbcan.2023.188890" />
	</analytic>
	<monogr>
		<title level="j">Biochim. Biophys. Acta Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">1878</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">188890</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">GPX4 in cell death, [35] autophagy, and disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Klionsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1080/15548627.2023.2218764</idno>
		<idno type="PMID">37272058</idno>
		<ptr target="http://dx.doi.org/10.1080/15548627.2023.2218764" />
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2621" to="2638" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">K</forename><surname>Wang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Mechanisms and regulations of ferroptosis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2023.1269451</idno>
		<idno type="PMID">37868994</idno>
		<ptr target="http://dx.doi.org/10.3389/fimmu.2023.1269451" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1269451</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1</title>
		<author>
			<persName><forename type="first">G</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-022-02537-x</idno>
		<ptr target="http://dx.doi.org/10.1038/s41388-022-02537-xPMID" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">36369321</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Trabectedin induces ferroptosis [38] via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zeng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cbi.2022.110262</idno>
		<idno type="PMID">36396105</idno>
		<ptr target="http://dx.doi.org/10.1016/j.cbi.2022.110262" />
	</analytic>
	<monogr>
		<title level="j">Chem. Biol. Interact</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page">110262</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Ferreira Dos Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Fuja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><forename type="middle">E C</forename><surname>Reichert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Cowman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Acuña Pilarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Tripp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Leibold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sirohi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Agarwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Koh</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-022-02460-1</idno>
		<idno type="PMID">36097192</idno>
		<ptr target="http://dx.doi.org/10.1038/s41388-022-02460-1" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">42</biblScope>
			<biblScope unit="page" from="4709" to="4723" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
		<idno>NLRP3</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">promotes tumor growth and metastasis in human oral squamous cell carcinoma</title>
		<idno type="DOI">10.1186/s12885-018-4403-9</idno>
		<idno type="PMID">29716544</idno>
		<ptr target="http://dx.doi.org/10.1186/s12885-018-4403-9" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">500</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><surname>Wang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">In vitro cell culture system optimization of keratinocytes from oral lichen planus ( OLP ) patients</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1111/odi.12599</idno>
		<idno type="PMID">27763705</idno>
		<ptr target="http://dx.doi.org/10.1111/odi.12599" />
	</analytic>
	<monogr>
		<title level="j">Oral Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="225" to="232" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">X</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">TGFβ3-mediated induction of Periostin facilitates head and neck cancer growth and is associated with metastasis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1038/srep20587</idno>
		<idno type="PMID">26857387</idno>
		<ptr target="http://dx.doi.org/10.1038/srep20587" />
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">20587</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Galangin in-[43] hibits growth of human head and neck squamous carcinoma cells in vitro and in vivo</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Dos Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fazeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Xavier Da Silva</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cbi.2014.10.027</idno>
		<idno type="PMID">25450235</idno>
		<ptr target="http://dx.doi.org/10.1016/j.cbi.2014.10.027" />
	</analytic>
	<monogr>
		<title level="j">Chem. Biol. Interact</title>
		<imprint>
			<biblScope unit="volume">224</biblScope>
			<biblScope unit="page" from="149" to="156" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Friedmann An</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Ferroptosis: mechanisms and implications for cancer development and therapy response</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Geli</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tcb.2023.04.005</idno>
		<idno type="PMID">37230924</idno>
		<ptr target="http://dx.doi.org/10.1016/j.tcb.2023.04.005" />
	</analytic>
	<monogr>
		<title level="j">Trends Cell Biol</title>
		<imprint>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1062" to="1076" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">PPT1 re-[45] duction contributes to erianin-induced growth inhibition in oral squamous carcinoma cells</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.3389/fcell.2021.764263</idno>
		<idno type="PMID">35004674</idno>
		<ptr target="http://dx.doi.org/10.3389/fcell.2021.764263" />
	</analytic>
	<monogr>
		<title level="j">Front. Cell Dev. Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">764263</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>De Morais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Almangush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Salo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><surname>Kujan</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Emerging histopathological parameters in the prognosis of oral squamous cell carcinomas</title>
		<author>
			<persName><forename type="first">O</forename><surname>Coletta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename></persName>
		</author>
		<idno type="PMID">37310089</idno>
	</analytic>
	<monogr>
		<title level="j">Histol. Histopathol</title>
		<imprint>
			<biblScope unit="page">18634</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">S-acylated Golga7b stabilises [47] DHHC 5 at the plasma membrane to regulate cell adhesion</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Woodley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Collins</surname></persName>
		</author>
		<idno type="DOI">10.15252/embr.201847472</idno>
		<idno type="PMID">31402609</idno>
		<ptr target="http://dx.doi.org/10.15252/embr.201847472" />
	</analytic>
	<monogr>
		<title level="j">EMBO Rep</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">47472</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Aramsangtienchai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Spiegelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><surname>S-Palmi</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">toylation of junctional adhesion molecule C regulates its tight junction localization and cell migration</title>
		<idno type="DOI">10.1074/jbc.M116.730523</idno>
		<idno type="PMID">28196865</idno>
		<ptr target="http://dx.doi.org/10.1074/jbc.M116.730523" />
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">292</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="5325" to="5334" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">The importance of [49] claudin-7 palmitoylation on membrane subdomain localization and metastasis-promoting activities</title>
		<author>
			<persName><forename type="first">S</forename><surname>Heiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zöller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Thuma</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12964-015-0105-y</idno>
		<idno type="PMID">26054340</idno>
		<ptr target="http://dx.doi.org/10.1186/s12964-015-0105-y" />
	</analytic>
	<monogr>
		<title level="j">Cell Commun. Signal</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Fröhlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dejanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kashkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schwarz</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Nussberg-</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">S-palmitoylation represents a novel mechanism regulating the mitochondrial targeting of BAX and initiation of apoptosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Er</surname></persName>
		</author>
		<idno type="DOI">10.1038/cddis.2014.17</idno>
		<idno type="PMID">24525733</idno>
		<ptr target="http://dx.doi.org/10.1038/cddis.2014.17" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">1057</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jiang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression</title>
		<author>
			<persName><forename type="first">B</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>He</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2020.03.008</idno>
		<idno type="PMID">32963941</idno>
		<ptr target="http://dx.doi.org/10.1016/j.apsb.2020.03.008" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharm. Sin. B</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1426" to="1439" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Flotillin-1 palmi-[52] toylation turnover by APT-1 and ZDHHC-19 promotes cervical cancer progression by suppressing IGF-1 receptor desensitization and proteostasis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pak</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41417-022-00546-2</idno>
		<idno type="PMID">36257975</idno>
		<ptr target="http://dx.doi.org/10.1038/s41417-022-00546-2" />
	</analytic>
	<monogr>
		<title level="j">Cancer Gene Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="302" to="312" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ojha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Noguera-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Rebecca</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Attana-</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Piao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Nicastri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ronghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Speicher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mastio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gimotty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Wherry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Gabrilovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Amaravadi</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci.insight.133225</idno>
		<idno type="PMID">32780726</idno>
		<ptr target="http://dx.doi.org/10.1172/jci.insight.133225" />
	</analytic>
	<monogr>
		<title level="j">JCI Insight</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page">133225</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12935-022-02508-y</idno>
		<idno type="PMID">35277179</idno>
		<ptr target="http://dx.doi.org/10.1186/s12935-022-02508-y" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell Int</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">115</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Saba-[55] tini, D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zoncu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bar-Peled</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Efeyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sancak</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1207056</idno>
		<idno type="PMID">22053050</idno>
		<ptr target="http://dx.doi.org/10.1126/science.1207056" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="issue">6056</biblScope>
			<biblScope unit="page" from="678" to="683" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Torii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shintoku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kubota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yaegashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Torii</surname></persName>
		</author>
		<imprint>
			<pubPlace>Sasa-</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">An essential role for functional lysosomes in ferroptosis of cancer cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yoshimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takeuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamada</surname></persName>
		</author>
		<idno type="DOI">10.1042/BJ20150658</idno>
		<idno type="PMID">26759376</idno>
		<ptr target="http://dx.doi.org/10.1042/BJ20150658" />
	</analytic>
	<monogr>
		<title level="j">Biochem. J</title>
		<imprint>
			<biblScope unit="volume">473</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="769" to="777" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">The role of ly-[57] sosome in regulated necrosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Alu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2020.07.003</idno>
		<idno type="PMID">33163342</idno>
		<ptr target="http://dx.doi.org/10.1016/j.apsb.2020.07.003" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharm. Sin. B</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1880" to="1903" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><surname>Xie</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Quercetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting ferroptosis via the Sirt1/Nrf2/Gpx4 pathway</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
		<idno type="DOI">10.3892/ijmm.2023.5321</idno>
		<idno type="PMID">37888753</idno>
		<ptr target="http://dx.doi.org/10.3892/ijmm.2023.5321" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">118</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Akiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Ostermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tcheng</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Yaz-</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Pryor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ii; Slngh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Baran</surname></persName>
		</author>
		<author>
			<persName><surname>Ay-Luo</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41375-023-02117-2</idno>
		<idno type="PMID">38148395</idno>
		<ptr target="http://dx.doi.org/10.1038/s41375-023-02117-2" />
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Ferroptosis as [60] an emerging target in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2023.1260839</idno>
		<idno type="PMID">37928554</idno>
		<ptr target="http://dx.doi.org/10.3389/fimmu.2023.1260839" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<date type="published" when="2023">2023, 14, 1260839</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhi</surname></persName>
		</author>
		<author>
			<persName><surname>The</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">mitochondrial regulation in ferroptosis signaling pathway and its potential strategies for cancer</title>
		<idno type="DOI">10.1016/j.biopha.2023.115892</idno>
		<idno type="PMID">37976895</idno>
		<ptr target="http://dx.doi.org/10.1016/j.biopha.2023.115892" />
	</analytic>
	<monogr>
		<title level="j">Biomed. Pharmacother</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page">115892</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Patanè</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Putaggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tellone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barreca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ficarra</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Ferroptosis: Emerging role in diseases and potential implication of bioactive compounds</title>
		<author>
			<persName><forename type="first">C</forename><surname>Maffei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Calderaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Laganà</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms242417279</idno>
		<idno type="PMID">38139106</idno>
		<ptr target="http://dx.doi.org/10.3390/ijms242417279" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page">17279</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Baruah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moorthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ramesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Padhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Govindaraju</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">A natural polyphenol activates and enhances GPX4 to mitigate amyloid-β induced ferroptosis in Alzheimer&apos;s disease</title>
		<idno type="DOI">10.1039/D3SC02350H</idno>
		<idno type="PMID">37712018</idno>
		<ptr target="http://dx.doi.org/10.1039/D3SC02350" />
	</analytic>
	<monogr>
		<title level="j">Chem. Sci</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="9427" to="9438" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.redox.2023.102952</idno>
		<idno type="PMID">37944384</idno>
		<ptr target="http://dx.doi.org/10.1016/j.redox.2023.102952" />
	</analytic>
	<monogr>
		<title level="j">Redox Biol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page">102952</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
